**Core Concept**
Raloxifene is a second-generation selective estrogen receptor modulator (SERM) used in the treatment of osteoporosis and prevention of breast cancer in postmenopausal women. It mimics the beneficial effects of estrogen on bone density while having minimal effects on the uterus and breast tissue.

**Why the Correct Answer is Right**
Raloxifene has several advantages over estrogen therapy in postmenopausal women. It has a lower risk of endometrial cancer, which is a significant concern with estrogen therapy. Additionally, raloxifene has been shown to have a beneficial effect on breast density, reducing the risk of breast cancer. Raloxifene also has a lower risk of blood clots compared to estrogen therapy.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because raloxifene is not associated with an increased risk of stroke or thromboembolic events, unlike estrogen therapy. Raloxifene may even have a protective effect against these conditions.
**Option B:** This option is incorrect because raloxifene is not associated with an increased risk of gallbladder disease, which is a concern with estrogen therapy.
**Option C:** This option is incorrect because raloxifene is not associated with an increased risk of vaginal bleeding, which is a common side effect of estrogen therapy.

**Clinical Pearl / High-Yield Fact**
Raloxifene's unique pharmacological profile makes it an ideal alternative to estrogen therapy in postmenopausal women, particularly those with a history of breast cancer or endometrial cancer.

**Correct Answer:** D